Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

  title={Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.},
  author={Z. Chen and Y. Lin and E. Barbieri and S. Burlingame and J. Hicks and A. Ludwig and J. Shohet},
  volume={11 8},
  • Z. Chen, Y. Lin, +4 authors J. Shohet
  • Published 2009
  • Biology, Medicine
  • Neoplasia
  • Neuroblastoma is derived from neural crest precursor components of the peripheral sympathetic nervous system and accounts for more than 15% of all pediatric cancer deaths. A clearer understanding of the molecular basis of neuroblastoma is required for novel therapeutic approaches to improve morbidity and mortality. Neuroblastoma is uniformly p53 wild type at diagnosis and must overcome p53-mediated tumor suppression during pathogenesis. Amplification of the MYCN oncogene correlates with the… CONTINUE READING
    MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
    • 57
    • Open Access
    MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
    • 42
    • Open Access
    Neuroblastoma models for insights into tumorigenesis and new therapies
    • 18
    Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
    • 8
    • Open Access
    WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma
    • 50
    • Open Access


    Publications referenced by this paper.
    MDM2 as a Critical Effector of the MYCN Oncogene in Tumorigenesis
    • 22
    • Open Access
    The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
    • 207
    • Open Access
    MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
    • 118
    • Open Access
    Targeted expression of MYCN causes neuroblastoma in transgenic mice
    • 661
    • Open Access
    Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.
    • 358
    • Open Access